TNFSF10 and hepatocellular carcinoma: By contrast, APO2L/TRAIL in combination with SM-164 inhibited cell viability by 83%, showing SM-164 potentiated APO2L/TRAIL activity in sensitive HCC cells (Fig. 2a).